{"schema_version":"1.0","type":"article","title":"再見自體CAR-T，台灣的泡沫也該破了","url":"https://drugnews.com.tw/articles/2026-04-27-car-t.html","markdown_url":"https://drugnews.com.tw/articles/2026-04-27-car-t.md","lang":"zh-Hant","date":"2026-04-27","publish_at":"2026-04-27T10:30:00+08:00","updated_at":"2026-04-27","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","自體免疫","臨床數據","生技投資"],"summary":"當市場還在用過去十年對自體 CAR-T 的理解框架看細胞治療時，異體 CAR-T 其實已經悄悄走到一個更關鍵的節點。","key_points":[],"facts":[],"sections":["異體 CAR-T 的歷史性一跳：Cema-cel 為什麼可能是細胞治療真正走向成藥的分水嶺","🔹01｜這件事厲害的地方，不只是數字漂亮，而是治療時點被改寫了","🔹02｜為什麼只有 12 位對 12 位，市場卻這麼在意？","🔹03｜真正超預期的，可能是安全性，而不是 MRD","🔹04｜風險其實還遠遠沒有解除","🔹05｜這不只是 Allogene 的好消息，也是台灣細胞治療敘事的壓力測試","🔹結語｜ALPHA3 不是終點，但它可能是異體 CAR-T 真正開始被重新定價的起點"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"\"Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL","source":"Allogene Therapeutics\"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"Allogene Therapeutics stock surges 36% on trial data By Investing.com","source":"","date":"","url":""},{"title":"Allogene Therapeutics stock surges 36% on trial data","source":"","date":"","url":""},{"title":"www.investing.com","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"BREYANZI","source":"FDA","date":"","url":""},{"title":"BREYANZI (lisocabtagene maraleucel) is a new cell-based #GeneTherapy treatment for adult patients with relapsed or refractory of certain types of large-B-cell #lymphoma.","source":"","date":"","url":""},{"title":"www.fda.gov","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma","source":"","date":"","url":""},{"title":"PURPOSELarge B-cell lymphomas (LBCLs) are curable, but patients with residual disease after therapy invariably experience progression. Ultrasensitive methods to detect circulating tumor DNA (ctDNA) as minimal residual disease (MRD) may improve the ...Impr","source":"","date":"","url":""},{"title":"ascopubs.org","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","source":"","date":"","url":""},{"title":"High-risk large B-cell lymphoma (LBCL) has poor outcomes with standard first-line chemoimmunotherapy. In the phase 2, multicenter, single-arm ZUMA-12 study (ClinicalTrials.gov NCT03761056) we evaluated axicabtagene ciloleucel (axi-cel), an autologous anti","source":"","date":"","url":""},{"title":"pubmed.ncbi.nlm.nih.gov","source":"","date":"","url":""},{"title":"\"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial - PubMed\"","source":"","date":"","url":""},{"title":"[6]:","source":"","date":"","url":""},{"title":"Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies","source":"","date":"","url":""},{"title":"PURPOSEOff-the-shelf, allogeneic CD19 chimeric antigen receptor (CAR) T-cell products may improve access to treatment versus autologous ones. We report the phase I experience of the allogeneic CD19 CAR T-cell product cemacabtagene ansegedleucel (cema-cel","source":"","date":"","url":""},{"title":"ascopubs.org","source":"","date":"","url":""},{"title":"[7]:","source":"","date":"","url":""},{"title":"[8]:","source":"","date":"","url":""},{"title":"www.sciencedirect.com","source":"","date":"","url":""},{"title":"https://www.sciencedirect.com/science/article/abs/pii/S2352302624002734","source":"","date":"","url":"https://www.sciencedirect.com/science/article/abs/pii/S2352302624002734"},{"title":"www.sciencedirect.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：再見自體CAR-T，台灣的泡沫也該破了（圖 1）","url":"https://drugnews.com.tw/assets/articles/car-t/dcard-01.webp"},{"alt":"Dcard 原圖：再見自體CAR-T，台灣的泡沫也該破了（圖 2）","url":"https://drugnews.com.tw/assets/articles/car-t/dcard-02.webp"},{"alt":"Dcard 原圖：再見自體CAR-T，台灣的泡沫也該破了（圖 3）","url":"https://drugnews.com.tw/assets/articles/car-t/dcard-03.png"},{"alt":"Dcard 原圖：再見自體CAR-T，台灣的泡沫也該破了（圖 4）","url":"https://drugnews.com.tw/assets/articles/car-t/dcard-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/car-t/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-04-27）。再見自體CAR-T，台灣的泡沫也該破了。https://drugnews.com.tw/articles/2026-04-27-car-t.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-04-27-car-t-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}